Idiosyncratic adverse drug reactions are unpredictable, dose independent and potentially life threatening; this makes them a major factor contributing to the cost and uncertainty of drug development. Clinical data suggest that many such reactions involve immune mechanisms, and genetic association studies have identified strong linkage between drug hypersensitivity reactions to several drugs and specific HLA alleles. One of the strongest such genetic associations found has been for the antiviral drug abacavir, which causes severe adverse reactions exclusively in patients expressing the HLA molecular variant B*57:01. Abacavir adverse reactions were recently shown to be driven by drugspecific activation of cytokine-producing, cytotoxic CD8 + T cells that required HLA-B*57:01 molecules for their function. However, the mechanism by which abacavir induces this pathologic T cell response remains unclear. Here we show that abacavir can bind within the F-pocket of the peptide-binding groove of HLA-B*57:01 thereby altering its specificity. This supports a novel explanation for HLA-linked idiosyncratic adverse drug reactions; namely that drugs can alter the repertoire of self-peptides presented to T cells thus causing the equivalent of an alloreactive T cell response. Indeed, we identified specific self-peptides that are presented only in the presence of abacavir, and that were recognized by T cells of hypersensitive patients. The assays we have established can be applied to test additional compounds with suspected HLA linked hypersensitivities in vitro. Where successful, these assays could speed up the discovery and mechanistic understanding of HLA linked hypersensitivities as well as guide the development of safer drugs.
Introduction
Abacavir is a nucleoside analog that suppresses HIV replication. In about 8% of recipients, abacavir is associated with significant immune mediated drug hypersensitivity, which is strongly associated with the presence of the HLA-B*57:01 allele (1, 2) . Three complementary models for the mechanism of immune mediated severe adverse drug reactions have traditionally been discussed(3, 4): The hapten (or prohapten) model states that drugs and their metabolites are too small to be immunogenic on their own, but rather act like haptens and modify certain self-proteins in the host that lead to immune recognition of the resulting hapten:self-peptide complexes as de novo antigens(5-7); The p-i model (short for pharmacological interaction with immune receptors) states that drugs can induce the formation of HLA:drug complexes that can activate T cell immune responses directly without requiring a specific peptide ligand (8) ; The danger model, which is in principle compatible with other models, states that danger signals other than the drug itself (such as chemical, physical or viral stress) are required to overcome immune tolerance barriers that otherwise suppress drug hypersensitivity reactions (7) .
None of these existing models provide a convincing mechanism for how abacavir induces adverse reactions through the activation of CD8 + cells in a strictly HLA-B*57:01 restricted manner, as was described in a ground breaking paper by the McCluskey group (2) . For the hapten hypothesis to apply, abacavir would need to modify one or more self-ligands that are solely presented by HLA-B*57:01 ( Figure 1) ; an unlikely proposition given that HLA molecules are known to fall in groups of overlapping binding specificity, and HLA-B*57:01 has a similar binding motif to the abacavir insensitive HLA-B*58:01 (9) . Also, no natural HLA specific drug haptenated peptide has been identified to date, although this has been attempted at least for carbamazepine (10, 11) . For the p-i model to apply, abacavir would need to bind to a unique surface patch of HLA-B*57:01 that is capable of inducing TCR recognition. However, the two residues that distinguish abacavir sensitive HLA-B*57:01 from insensitive HLA-B*57:03 are located at the bottom of the HLA binding groove and are unlikely to contact the T cell receptor. Finally, the danger model may well be relevant for abacavir adverse reactions, but does not explain its HLA restriction. We find an alternative hypothesis more attractive, namely that the binding groove of HLA-B*57:01 can accommodate abacavir (12) , thereby altering the repertoire of self-peptide ligands that is 3 bound and presented (2, 10) . This could lead to a primary and polyclonal immune response, which is in line with observations that abacavir can induce a relatively diverse response in T cells from abacavir naïve individuals after in vitro stimulation for 11 days(2) with broad usage of V beta receptors by the responding T cells (2) . However, to date there has been no experimental evidence that supports this 'altered self repertoire' hypothesis as a mechanism for drug hypersensitivity.
Results
To determine whether abacavir can impact the peptide-binding specificity of HLA-B*57:01, we tested its binding affinity using positional scanning combinatorial peptide libraries (13) in the presence and absence of the drug. Each library consisted of 9-mer peptides that shared the same residue at one position, but were otherwise random in sequence. In the absence of abacavir, our binding measurements reproduced the known motif of HLA-B*57:01 for C-terminal peptide residues, namely a preference for large hydrophobic residues such as tryptophan and phenylalanine, and disfavoring small hydrophobic residues like alanine and valine (Figure 2A ). We were specifically interested in residues showing an increased affinity in the presence of abacavir, which could potentially lead to presentation of de novo peptides. The most dramatic gain was found for peptides with C-terminal valine (8.8 fold increase), alanine (6.7 fold increase), and isoleucine (5.5 fold increase). The only other residue with a 5-fold or higher increase was leucine at position 7 (SI Appendix, Table S1 ). In contrast, the control MHC molecule HLA-B*58:01 showed no increases in affinity above a factor of 3 for any residue at any position ( Figure 2B and SI Appendix, Table S2 ).
Based on these results we synthesized individual peptides with the sequence HSITYLLPV (pep-V) and HSITYLLPW (pep-W). Residues 1-8 of these peptides were chosen based on their high affinity in combinatorial library scans in the presence of abacavir. The C-terminus was chosen so that pep-V was expected to be unable to bind efficiently in the absence of abacavir, but would do so in its presence. As a control, pep-W with a C-terminal tryptophan was expected to be able to bind HLA-B*57:01 readily in the presence or absence of abacavir. The peptides were radiolabeled and tested for binding in increasing concentrations of abacavir. Peptide binding assays demonstrate that pep-V requires abacavir in a dose-dependent manner to bind a detectable amount of peptide ( Figure 2C ), while pep-W bound well regardless of the presence or absence of abacavir ( Figure 2D ). Similar results were obtained using two independent peptide-HLA-B*57:01 interaction assays measuring either binding (14) or stability (15) (SI Appendix, Figure S1 ) and an additional control allele, HLA-B*57:03 (SI Appendix, Table S3 ). In summary, we found that specific peptides such as pep-V have a significantly increased affinity for HLA-B*57:01 in the presence of abacavir, that this effect is abolished when switching the C-terminal P9 residue to a tryptophan (pep-W), and that this effect is not observed for control HLA alleles.
Structural analysis was used to further dissect the mechanism by which abacavir may facilitate the binding of pep-V to HLA-B*57:01. Computational solvent mapping (16) , molecular docking (17) , and molecular dynamics simulations (18) of 30ns in length identified a potential binding site for abacavir localized to the F-pocket in the vicinity of residue Ser 116 that was shown to be required for abacavir T cell recognition(2) (SI Appendix, Figure S2 ). In contrast, a similar protocol did not identify stable complexes of MHC, abacavir and peptide with either pep-W or abacavir insensitive HLA-B*57:03.
To directly test our hypothesis that abacavir binds within the antigen-binding cleft, we solved the X-ray crystal structure of HLA-B*57:01 bound to pep-V in the presence of abacavir. We believe that choosing pep-V instead of a ligand with a large side chain at the C-terminus such as those used in previous crystal structures (2) was crucial for obtaining crystals that could resolve the location of abacavir. The structure was refined to an R value of 18 % and R free of 22 % using X-ray diffraction data to 2.0 Å (PDB ID 3UPR; see Methods for details and SI Appendix, Table S4 for full refinement statistics). Abacavir is bound to a 4 largely hydrophobic pocket in the antigen-binding cleft forming van der Waals contacts with both HLA-B*57:01 (Tyr9, Tyr 74, Ile 95, Val97, Tyr99, Tyr123, Ile 124, Trp147) and pep-V (HSITYLLPV) (Ile3, Leu7, Val9) ( Figure 3A and SI Appendix, Figure S3 ). To determine if the conformation of pep-V is altered by abacavir binding compared to conventionally presented peptides, we compared our structure to four published structures of peptides bound to HLA-B molecules. As shown in Figure 3D , the main chain conformation of pep-V is similar to other peptides bound to HLA-B. The amino-and carboxy-termini of pep-V and the other HLA-B bound peptides shown in Figure 3D are buried in the A and F pockets, respectively, forming conventional contacts with highly conserved residues. The central portion of the pep-V main chain is within the range of variability demonstrated by other peptide/HLA-B complexes. The pep-V main chain does not protrude in a central bulge as does the longer 11-mer peptide bound to HLA-B*35:01. These data suggested that pep-V in the presence of abacavir is bound in a regular antigen conformation allowing for conventional recognition by TCRs rather than requiring hapten or superantigen recognition modes (19, 20) .
Only two residues, Asp114 and Ser116, distinguish HLA-B*57:01 from the abacavir insensitive allele HLA-B*57:03. Abacavir interacts directly with these residues (Figures 3C and 3E) . The Oδ1 atom of Asp114 is within H bonding distance of the main purine group N2 and N3 atoms of abacavir. The hydroxyl group of Ser116 forms an H bond with the 2-amino group on the purine ring of abacavir. The exchange of Ser116 to Tyr116 which is found in HLA-B*57:03 is expected to disrupt these interactions. Indeed, it was shown that this single residue exchange is sufficient to abrogate abacavir associated recognition by CD8 + T cells (2) . The HLA-B*58:01 allelic variant is also very similar to HLA-B*57:01. These molecules have identical amino acids at positions 114 and 116, but differ at five other positions. These include Val97 which is part of the hydrophobic pocket in HLA-B*57:01 that forms van der Waals contacts with abacavir (SI Appendix, Figure S3) , and is replaced with a charged Arg97 in HLA-B*58:01 abrogating these interactions. In addition, the structure reveals that the side chain of Val9 of pep-V is within van der Waals contact distance of the cyclopropyl moiety of abacavir. Finally, the contact made between the Leu7 residue of the peptide and abacavir explains why the MHC binding assays showed that this residue had the highest increase in affinity in the presence of abacavir apart from C-terminal residues. In summary, our findings give a structural explanation for why distinct repertoires of peptides with short hydrophobic P9 side chains are bound by HLA-B*57:01 in the presence of abacavir, whereas other HLA alleles are unaffected.
To explore the biologic relevance of these findings, we determined whether live cells treated with abacavir present a different set of self-peptides on HLA-B*57:01 molecules than untreated cells. Our binding assays predicted that HLA-B*57:01 in the presence of abacavir would favor presentation of peptides having a small C-terminal residue such as valine and isoleucine rather than tryptophan and phenylanine normally preferred by HLA-B*57:01 molecules. To answer this question, peptides were eluted from a HLA-B*57:01 single allele transfected 721.221 cell line (21) treated with and without abacavir. Eluted peptides were analyzed by nanoflow-HPLC coupled to an Orbitrap mass spectrometer equipped with a front-end electron transfer dissociation (FETD) (22, 23) . We identified 539 and 682 peptide sequences from the drug treated and untreated samples, respectively, 287 of which were found in both samples (SI Appendix, Table S5 ). No peptides with valine at the C-terminus were identified in untreated cells, but fifteen peptides with valine at the C-terminus were identified in the presence of abacavir. Three of these peptides were present at levels (>100 copies/cell) that place them among the top 5% of all peptides in the drug treated sample. Table 1 compares the frequency of C-terminal residues in peptides identified uniquely in either the abacavir treated or untreated samples. In the presence of abacavir, we found not only a significant enrichment for peptides with valine at the Cterminus, but also for isoleucine. In contrast, there were significantly fewer peptides with tryptophan and phenylalanine at the C-terminus. The results for these residues exactly matched the predictions made by the binding assays. In contrast to valine, no peptides with C-terminal alanine were discovered in the presence of abacavir, even though both showed a similar increase in affinity. However, the absence of peptides with an alanine at the C-terminus can be explained by the antigen processing machinery including proteasomal cleavage and TAP transport, which restricts the peptide repertoire available for binding to MHC, and disfavors peptides with C-terminal alanine (24, 25) . In summary, we find that the self-peptide repertoire presented by HLA-B*57:01 positive cells in the presence of abacavir is significantly altered in a manner that is consistent with results obtained from the molecular MHC binding assays.
Finally, we set out to determine if we could detect T cells in hypersensitive patients that recognize HLA B*57:01 restricted peptides that are presented only in the presence of abacavir. Of note, we did not expect high frequency T cell responses against any individual peptide, as the altered ligand mechanism suggested that the response was directed against a very large number of different peptides. We screened PBMCs from five HLA-B*57:01 positive donors with a clinical history of abacavir hypersensitivity for recognition of peptides with valine at the C-terminus that were identified following elution from abacavir treated HLA-B*57:01 cells. PBMCs were incubated for 15 minutes with a high concentration of 10 μg/ml endogenous peptides in the presence of 100 μg/ml abacavir followed by washing to optimize loading of HLA B*57:01 with the specific exogenously added peptide(s) and reduce abacavir entering cells and enabling presentation of other endogenous ligands. After a first round of screening four pools of 3-4 peptides in ELISPOT assays using PBMCs from two donors with sufficient samples available, the peptides from the pool with the highest response (pool 1) were tested individually. Peptide VTTDIQVKV gave the highest response in this screen (SI Appendix, Figure S4 ). Subsequently, we tested the four pools and the individual peptide VTTDIQVKV in the remaining three donors. As shown in Figure 4 , a significantly higher response was detected when cells were pulsed with peptide VTTDIQVKV and abacavir compared to the response against cells pulsed with either abacavir alone or peptide alone. These data demonstrated that memory T cell responses in abacavir hypersensitive donors were directed against a self-peptide that required abacavir to efficiently bind HLA B*57:01.
Discussion
Our findings provide a mechanistic explanation for abacavir-induced adverse drug reactions. We found that abacavir can bind inside the peptide binding groove of HLA-B*57:01, thereby enabling the presentation of peptide ligands that normally cannot bind in substantial amounts. Since T cells are generally tolerant only to MHC-restricted peptide ligands presented during T cell development in the thymus (26) , presentation of an altered repertoire of class I MHC binding peptides will be perceived as being foreign and trigger CD8 + T cell responses. These responses have been previously demonstrated to be a hallmark of patients with abacavir hypersensitivity (2) . Although abacavir is metabolized inside cells (27, 28) , our finding that HLA-B*57:01 is affected by the abacavir parent drug suggests that the parent drug itself is present during peptide loading in the ER. Indeed, others have detected unaltered intracellular abacavir which rapidly co-localizes with HLA-B57 in the endoplasmic reticulum (27, 29) . Abacavir might well be delivered to the ER directly from the extracellular medium without traversing the cytosol, as was described for HLA class I binding peptides (30). In this context, it should also be noted that only a small fraction of peptide:MHC loading events have to be affected by abacavir to cause a physiological effect as T cells have a very high sensitivity to detect non-self peptides which is essential to their function, and remarkably few peptide:MHC complexes are sufficient to trigger a T cell response(31, 32).
These biochemical and structural findings provide an explanation for why, of the more than 5000 Class I MHC alleles, only HLA-B*5701 is affected by abacavir. This also provides support for the altered peptide 6 model where the drug in effect creates a novel HLA-B allele presenting self-peptides to which the host has not been toleralized, analogous to the situation occurring in mismatched HLA organ transplantation. In organ transplantation, it has recently been reported that pre-existing Class I restricted effector memory T-cell responses to prevalent viral infections can mediate organ rejection (33). This model of heterologous immunity may explain the clinical manifestations that arise from drug-induced altered peptide presentation, and why only 55% of HLA-B*5701 positive patients treated with abacavir develop hypersensitivity. Other explanations for the incomplete positive predictive value of specific HLA alleles for abacavir and other drug hypersensitivity syndromes and the varying clinical features is that the relevant peptide recognized by drug specific T-cells in the presence of drug is itself genetically polymorphic and/or only present in some patients or tissues or that only some patients have a T-cell clonotype able to respond to the neo-antigen(34).
Over the last 10 years in particular there have been many reported HLA-associated drug toxicities(4). Further studies should explore in detail if the mechanism for HLA-linked adverse reactions to abacavir applies to adverse reactions against other small molecules that seem to be immune mediated and HLA linked, such as chronic beryllium disease(35) adverse reactions to allopurinol(36) or carbamazepine(37). Our methods and findings are particularly significant for such studies as they can be utilized to identify the structural, biochemical and functional basis of potential HLA associated T-cell mediated drug hypersensitivities before use of a drug in man. This may have utility both in excluding high risk compounds from further development, and guiding the design of compounds that do not bind risk HLA alleles or alter the repertoire of peptides presented. The biochemical and functional assays described could also be used to characterize the HLA restriction and likely immunopathogenesis of cases of hypersensitivity in early clinical studies. This could facilitate the early introduction of HLA screening as has been successfully implemented for the prevention of abacavir hypersensitivity (38), rather than having to rely exclusively on genetic association studies that require large cohorts of affected patients. Finally, these findings have potential relevance for a broader understanding of HLA associations in the immunopathogenesis of autoimmune diseases, infectious diseases and cancer. Such associations can be strong, yet remain enigmatic, because the molecular recognition events underlying the associations are unclear. The discovery that a small-molecule drug can bind within the antigen-binding cleft of MHC and alter the repertoire of presented peptides suggests new mechanisms of action as the causative basis for HLA associations. HLA-associated disorders may be perpetuated by drugs, small molecules of environmental origins or self-metabolites that bind within the antigen-binding cleft and alter peptide binding.
Materials and Methods
X-ray crystallography. Refolded β 2 -microglobulin, HLA-B*57:01 and abacavir formed crystals at 4 mg per ml in 0.17 M sodium acetate trihydrate, 0.1 M sodium cacodylate, pH 6.5, 25% PEG 8,000, 15% glycerol which belong to the space group P2 1 with unit cell dimensions a=44.8 Å, b=130.7 Å, c=88.3 Å, α=90 o , β=104.6 o , γ=90 o . Two peptide/abacavir/HLA complexes in the asymmetric unit were identified by molecular replacement using coordinates for the heavy chain and β 2 -microglobulin from PDB 2RFX (HLA-B*57:01 bound to LSSPVTKSF). The peptide and ligands were not included in the molecular replacement model. Unambiguous electron density for the peptide and abacavir were visible in Fo-Fc difference maps and simulated annealing omit electron density maps. The structure was refined to an R value of 18% and R free of 21% using X-ray diffraction data to 2.0 Å.
The best crystals diffracted to a high-resolution limit of 1.9 Å. The crystals belonged to space group P2 1 and contained two HLA heterodimers (heavy chain HLA-B*57:01 and light chain β 2 -microglobulin) in the asymmetric unit. The phasing was done by molecular replacement and the initially calculated Fo-Fc difference map showed unambiguous electron density for both the peptide and the abacavir drug.
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Abundance calculation for eluted peptides. Peptide abundances were determined by comparing the ion current observed for 100 fmol of an internal standard, angiotensin I (DRVYIHPFHL), to that observed for individual peptides. This femtomole quantity was then converted to peptide molecules by multiplying by Avogadro's number and to molecules (copies)/cell by dividing this number by the total number of cells employed to generate the sample aliquot injected into the mass spectrometer.
T cell ELISPOT assays. Clinical samples: Informed consent was obtained from all patients and studies approved by both the Royal Perth Hospital and Murdoch University ethics committees, Perth, Western Australia Cryopreserved PBMC from abacavir hypersensitive patients of time-points previously evaluated by abacavir specific ELISpot assay were thawed and cultured O/N in RPMI 1640 media containing 10% fetal calf serum (FCS), 50 U/ml Penicillin, 50 μg/ml streptomycin and 1mM sodium pyruvate O/N (F10 medium)(Life Technologies). The assays were controlled using a unstimulated PBMC control, a positive control for abacavir induced endogenous ligand consisting of 10 μg/ml of abacavir added for the length of the assay culture, an abacavir 15 minute pulse and wash control to control for effects of the pulse on inducing endogenous peptide targets. Peptide +/-abacavir incubation times were derived to achieve the best balance between detection of enhanced exogenous peptide binding and a restriction of abacavir induced endogenous peptide presentation. To setup the assay, 5 x 10 5 PBMC, were then exposed to 10 μg/ml exogenous peptides, either singly or as peptide pools containing up to 4 peptides, in the presence of absence of 100 μg/ml abacavir for 15 minutes within a 37°C cell culture incubator. The cells were then immediately washed with 25 volumes of ice cold RPMI 1640 cell culture media and centrifuged for 10 minutes at 300g at 4°C. Cells were then re-suspended in 450 μl of F10 medium containing 20U/ml rh IL-2 (Peprotech). 2 x 10 5 PBMC in duplicate were then transferred into MAIPS4510 ELISpot plates coated with 2 μg/ml anti-IFN-γ antibody (1-D1k, Mabtech) and blocked with F10 medium. Cells were cultured O/N in a 37°C cell culture incubator. The following day the plates were washed with sterile PBS and incubated with anti-IFN-γ biotinylated antibody (7-B6-1, Mabtech) for 2 hours, washed and incubated for 1 hour with streptavidin-HRP and then washed. Plates were substrated for 8-12 minutes using TMB substrate (Mabtech). Plates were air dried and then counts evaluated using an AID automated microplate ELISpot Reader (AID GmbH. Strassberg, Germany). The sequences of the peptides tested were as follows, Pool 1: KTIHLTLKV, RTLAEIAKV, VTTDIQVKV, TVAPFNPTV. (13, 39) . Results for libraries with different C-terminal residues are shown for those residues with affinities of 5,000 nM or better -a minimal threshold for binding. Error bars indicate 95% confidence intervals for the mean, and residues marked with an asterisk * had significantly different IC50 values in the presence vs. absence of abacavir (p < 0.001, two-tailed Student's t-test comparing log(IC50) values). The most pronounced affinity increases for HLA-B*57:01 in the presence of 1mg/ml abacavir were found for peptides with a valine at the C-terminus, which increase more than 8-fold in affinity, followed by alanine and isoleucine (all above 5-fold). In contrast, the maximum affinity increase for any peptide library binding to HLA-B*58:01 was less than 3-fold. PBMCs from five HLA-B*57:01 positive donors with a clinical history of abacavir hypersensitivity were pulsed for 15 minutes with peptide antigens in the presence or absence of abacavir, or with abacavir alone, washed and then tested by IFN-γ ELISpot assay (see methods for details). The figure shows the calculated mean (± SEM) IFN-γ spots per million input PBMC. Statistically significant responses compared to the response induced by the abacavir pulse alone were obtained for peptide pool 1 and the individual peptide VTTDIQVKV (paired two tailed Student t-test on the square root of the SFC counts). Incubating PBMCs from these donors with 10 μg/ml abacavir overnight gave an average of 200 ± 63 SFC per million. Figure S1 : Binding of pep-V to B*57:01 in AlphaScreen and dissociation assay.
Supporting Information
A) The affinity of pep-V (KSSQVHIPV) to biotinylated recombinant B*57:01 was determined with and without adding 1.0 mg/ml abacavir using an AlphaScreen receptor binding assay (1) based upon streptavidin coated donor-beads and W6/32 (anti-HLA class I antibody) coated acceptor-beads. In the presence of abacavir peptide KSSQVHIPV was a good binding peptide, K D =207 nM, whereas in the absence of abacavir peptide KSSQVHIPV was a very weak binder, K D =18,000 nM. B) Bound HLA-B*57:01: pep-V complexes are detected in a scintillation proximity assay (SPA, (2)) using radiolabelled B2m and recombinant biotinylated MHC in a streptavidin coated SPA microplate. The signal is generated when B2m* is bound to the bottom of the plate which only occurs in presence of a bound peptide. The dissociation measurement is started by adding excess of unlabelled B2m and raising the temperature to 37C. Measurements are made in 17 minute intervals, creating a dissociation curve. Table S3 compares different dissociation curves of combinatorial peptide libraries using the area under the dissociation curve (AUC) as a metric divided by the AUC value of the completely randomized library and normalized to an average value of 1. 
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R free is calculated in the same manner based on 10% of the reflection data not used during refinement. 
